Avania Acquires MAXIS, Advancing MedTech Leadership in Pre-Clinical, Regulatory Strategy, and Clinical Expertise

Avania, a leading, global medical technology contract research organization (CRO),announced its acquisition of MAXIS, a prominent medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management. MAXIS has offices in San Jose, California, and Frankfurt am Main, Germany, with additional operational staff across the regions. With MAXIS, the combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).

Recommended AI News: LZG International, Inc. (FatBrain AI) Announces Plans to Uplist to OTCQB Venture Market

Global #MedTech leader @AvaniaClinical acquires MAXIS, bolstering leadership and expertise across pre-clinical, clinical, and regulatory for emerging and advanced medical devices.

“This acquisition strengthens our position as the leading MedTech focused CRO, advancing innovative medical technologies from ideation to commercialization, providing a range of highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs,” said Sapna Hornyak, president and CEO of Avania. “The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow.”

MAXIS clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the U.S., EU, and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, data analytics, and medical writing.

Recommended AI News: Introducing WordPress VIP for Salesforce: a Powerful, Time-saving Integration for Content Marketers

MAXIS’ long-standing commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources,” said Kathleen Marshall, president of MAXIS Medical. “Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”

Avania customers will benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and Software as Medical Device), and regulatory consulting space. Further, MAXIS bolsters the Avania depth across innovative technologies and multiple therapeutic areas.

Recommended AI News: Prisma Cloud Delivers Context-Aware Software Composition Analysis to Secure Deployment of Open Source Software

[To share your insights with us, please write to sghosh@martechseries.com]